Moreover, among the individuals receiving EGFR‐TKIs combined with thoracic radiotherapy or radiotherapy for bone metastasis, those harboring the 19‐Del mutation exhibited better OS than those harboring the 21‐L858R mutation. The gene discussed is EGFR; the disease is bone metastasis.